Superworth

Amylyx Pharmaceuticals price to sales ratio AMLX

Market value divided by revenue over the last twelve months, since 2023.

Today, Oct 23, 2026
n/m
not a meaningful number
Last meaningful
2.4×
May 2025
Peer median
2.6×

Amylyx Pharmaceuticals' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in May 2025, at 2.4×.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

YearEnd of yearLowHigh
20252.4×1.1×2.4×
20241.4×0.3×3.9×
20233.4×2.8×7.7×

Against its peers

Companies in Drug Manufacturers - General nearest Amylyx Pharmaceuticals' size, closest first, today.

CompanyPrice to sales ratio
AMLXAmylyx Pharmaceuticalsn/m
NRIXNurix Therapeutics3.9×
OGNOrganon0.6×
LQDALiquidia8.5×
ARQTArcutis Biotherapeutics8.5×
PBHPrestige Consumer Healthcare2.0×
INDVIndivior Pharmaceuticals3.1×
HRMYHarmony Biosciences2.2×
ANIPANI Pharmaceuticals1.7×
PAHCPhibro Animal Health1.0×
KNSAKiniksa Pharmaceuticals International7.1×
Peer median2.6×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Amylyx Pharmaceuticals

Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.